Oncolytics Completes 100-Litre cGMP Production of REOLYSIN

Oncolytics has completed an initial 100-litre production run of REOLYSIN under cGMP conditions with the support of its contract manufacturer, SAFC Pharma. The company is now preparing for the commercial launch of REOLYSIN.

Matt Coffey, chief operating officer of Oncolytics, said: “The manufacturing program is an integral part of the company’s development plan for REOLYSIN. With the clinical results reported to date and the expected initiation of our pivotal program this year, keeping pace with the manufacturing process is critical.”

Oncolytics is a Calgary-based biotechnology firm. The company is focused on the development of oncolytic viruses as potential cancer therapeutics.